Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$65.34 0.54 (0.83%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 122,563,000
Market Cap: 8.01(B)
Last Volume: 8,264,325 Avg Vol: 8,241,262
52 Week Range: $26.88 - $108.06
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 138,376 249,012 432,485 896,841
Total Sell Value $10,230,342 $16,723,328 $23,122,951 $44,047,420
Total People Sold 3 4 5 11
Total Sell Transactions 7 18 40 83
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 710
  Page 1 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Henderson John T Director   •       •      –    2024-04-25 4 AS $64.54 $681,671 D/D (10,562) 32,070 1%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-12 4 GD $0.00 $0 D/D 150 138,417     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-09 4 S $74.31 $2,422,918 D/D (32,605) 138,567 14%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-09 4 OE $6.67 $190,795 D/D 28,605 171,172     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-14 4 A $0.00 $0 D/D 16,941 63,887     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-14 4 A $0.00 $0 D/D 21,333 142,567     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-14 4 A $0.00 $0 D/D 4,079 29,664     -
   Blum Robert I President & CEO   •       •      –    2024-03-14 4 A $0.00 $0 D/D 61,490 461,221     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-06 4 D $66.88 $341,289 D/D (5,103) 46,946     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-06 4 D $66.88 $57,316 D/D (857) 25,585     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-06 4 D $66.88 $542,330 D/D (8,109) 121,234     -
   Blum Robert I President & CEO   •       •      –    2024-03-06 4 D $66.88 $1,118,568 D/D (16,725) 399,731     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-05 4 AS $67.53 $2,202,606 D/D (32,604) 138,973 -2%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-05 4 OE $6.67 $190,789 D/D 28,604 167,577     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-04 4 D $67.68 $149,031 D/D (2,202) 52,049     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-04 4 D $67.68 $120,673 D/D (1,783) 26,442     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-04 4 D $67.68 $651,758 D/D (9,630) 133,343     -
   Blum Robert I President & CEO   •       •      –    2024-03-04 4 D $67.68 $1,715,079 D/D (25,341) 416,456     -
   Henderson John T Director   •       •      –    2024-02-14 4 AS $76.48 $382,400 D/D (5,000) 42,632 -15%     
   Henderson John T Director   •       •      –    2024-02-14 4 OE $4.44 $22,200 D/D 5,000 47,632     -
   Blum Robert I President & CEO   •       •      –    2024-02-13 4 AS $76.85 $960,625 D/D (12,500) 441,797 -15%     
   Blum Robert I President & CEO   •       •      –    2024-02-13 4 OE $6.67 $83,375 D/D 12,500 454,297     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-02-06 4 AS $79.28 $2,585,497 D/D (32,605) 142,973 -18%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-02-06 4 OE $6.67 $190,795 D/D 28,605 175,578     -
   Blum Robert I President & CEO   •       •      –    2024-01-31 4 AS $79.57 $994,625 D/D (12,500) 441,797 -16%     
  710 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us